Vir Biotechnology (NASDAQ:VIR) Price Target Lowered to $26.00 at Barclays

Vir Biotechnology (NASDAQ:VIR) had its price objective decreased by Barclays from $28.00 to $26.00 in a research note issued to investors on Monday morning,Benzinga reports. Barclays currently has an overweight rating on the stock.

VIR has been the subject of a number of other reports. Needham & Company LLC reissued a “buy” rating and set a $19.00 price objective on shares of Vir Biotechnology in a research report on Friday, November 1st. HC Wainwright reiterated a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a research report on Tuesday, August 20th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $36.40.

Vir Biotechnology Trading Down 3.9 %

NASDAQ:VIR opened at $9.77 on Monday. The company has a market cap of $1.35 billion, a P/E ratio of -2.51 and a beta of 0.46. Vir Biotechnology has a twelve month low of $7.12 and a twelve month high of $13.09. The company’s 50-day moving average price is $7.83 and its 200-day moving average price is $8.90.

Vir Biotechnology (NASDAQ:VIR) last issued its earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.51). The company had revenue of $2.38 million during the quarter, compared to analyst estimates of $5.54 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The firm’s revenue was down 9.8% compared to the same quarter last year. During the same period last year, the business earned ($1.22) earnings per share. On average, analysts expect that Vir Biotechnology will post -3.48 earnings per share for the current year.

Insider Transactions at Vir Biotechnology

In other Vir Biotechnology news, Director Janet Napolitano sold 12,190 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $7.80, for a total transaction of $95,082.00. Following the sale, the director now owns 11,616 shares of the company’s stock, valued at approximately $90,604.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last ninety days, insiders sold 15,940 shares of company stock valued at $127,410. 15.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Vir Biotechnology

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Innealta Capital LLC purchased a new position in shares of Vir Biotechnology during the second quarter worth about $32,000. Blue Trust Inc. lifted its position in Vir Biotechnology by 143.5% during the 3rd quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock worth $30,000 after acquiring an additional 2,351 shares during the period. nVerses Capital LLC purchased a new position in shares of Vir Biotechnology in the 3rd quarter valued at approximately $56,000. Magnetar Financial LLC acquired a new position in shares of Vir Biotechnology in the second quarter valued at approximately $95,000. Finally, Headlands Technologies LLC purchased a new stake in shares of Vir Biotechnology during the first quarter worth approximately $119,000. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).